The Authors’ Reply

被引:0
作者
John-Joseph Borg
George Aislaitner
Michal Pirozynski
Stephen Mifsud
机构
[1] Medicines Authority,Department of Anaesthesiology and Critical Care Medicine
[2] National Organization for Medicines (EOF),undefined
[3] Postgraduate Medical School,undefined
[4] Permanent Representation of Malta to the European Union,undefined
关键词
Marketing Authorization; Drug Approval; Legislative Framework; Risk Management Plan; Regulatory Tool;
D O I
10.2165/11592690-000000000-00000
中图分类号
学科分类号
摘要
引用
收藏
页码:530 / 531
页数:1
相关论文
共 4 条
[1]  
Callréus T(2011)The new EU legislation on pharmacovigilance and changing models for drug development Drug Saf 34 529-30
[2]  
Borg JJ(2011)Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance Drug Saf 34 187-97
[3]  
Aislaitner G(undefined)undefined undefined undefined undefined-undefined
[4]  
Pirozynski M(undefined)undefined undefined undefined undefined-undefined